Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
NCT ID: NCT01355406
Last Updated: 2018-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
257 participants
INTERVENTIONAL
2011-09-16
2018-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The intent of this study is to demonstrate that the FlexStent® Femoropopliteal Self-Expanding Stent System is safe and effective for the treatment of patients with peripheral arterial disease. Specifically, the FlexStent® shall meet or exceed the proposed safety and efficacy performance goals established for Femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Efficacy and Safety of the FlexStent Self-Expanding Stent System
NCT01071460
Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis
NCT00530712
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
NCT01820637
EverFlex Post Approval Study
NCT01680835
Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions
NCT07122167
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PAD
This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at \> 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
FlexStent® Femoropopliteal Self Expanding Stent System
Transcatheter over guidewire placement of an intravascular stent(s)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FlexStent® Femoropopliteal Self Expanding Stent System
Transcatheter over guidewire placement of an intravascular stent(s)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects, male or female, must be at least 35 years of age at the time of consent. A female of childbearing potential may be enrolled, provided she has a negative pregnancy test within 7 days of screening.
2. Subjects must give written informed consent prior to participation in the study and must understand the purpose of this study and be willing to adhere to the study procedures described in this protocol.
3. Rutherford Classification Category 2-4
4. De novo lesion in the Femoropopliteal artery, including the entire extent of the superficial femoral artery and the proximal portion of the popliteal artery extending to the medial condyle 3 cm above the knee joint
5. Disease segment length ≤ 180 mm
6. \>70% diameter stenosis and/or occlusion based on site-determined visual angiography
7. Patent ipsilateral iliac artery
8. Patency of ipsilateral mid/distal popliteal artery and at least 1 tibial artery with no planned intervention
9. Target reference vessel diameter 3.5-7.5 mm.
10. Projected life expectancy of 12 months or greater
11. Patient is available for follow-up for 36 months and is willing and able to comply with all follow-up requirements
12. Patient is willing and able to provide signed informed consent
Exclusion Criteria
1. Target vessel previously treated with a stent
2. Target lesion within 1.5 cm of the ostium of the SFA
3. Rutherford Classification Category 0,1,5 or 6
4. Inability to tolerate antithrombotic or antiplatelet therapies
5. Pregnancy (female of child-bearing age confirmed pregnant)
6. Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of complying with protocol follow up.
7. Serum creatinine \> 2.5 mg/dL
8. Myocardial infarction or stroke within 30 days of treatment date
9. Known hypercoagulable state
10. Known bleeding diathesis
11. Untreated angiographically-evident thrombus in target vessel
12. Patients currently enrolled in any other clinical trial
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Prairie Education and Research Cooperative
INDUSTRY
Cordis Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William A. Gray, MD
Role: PRINCIPAL_INVESTIGATOR
Center for Interventional Vascular Therapy / Columbia University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abrazo Health Care Clinical & Trans. Research
Phoenix, Arizona, United States
Yuma Regional Medical Center
Yuma, Arizona, United States
El Camino Hospital
Mountain View, California, United States
Yale University/New Haven Hospital
New Haven, Connecticut, United States
Manatee Memorial Hospital
Bradenton, Florida, United States
Florida Research Network
Gainesville, Florida, United States
Memorial Hospital
Jacksonville, Florida, United States
Baptist Cardiac & Vascular Institute
Miami, Florida, United States
Mount Sinai Miami Medical Center
Miami Beach, Florida, United States
Florida Hospital Pepin Heart Institute
Tampa, Florida, United States
University Hospital
Augusta, Georgia, United States
St. John's Hospital
Springfield, Illinois, United States
Midwest Cardiovascular Research Foundation / Trinity Medical Center
Davenport, Iowa, United States
Healient Physician Group
Overland Park, Kansas, United States
Lafayette General Medical Center
Lafayette, Louisiana, United States
Christus St. Patrick Hospital
Lake Charles, Louisiana, United States
Glenwood Regional Medical Center
West Monroe, Louisiana, United States
Washington Adventist Hospital / Center for Cardiac & Vascular Research
Takoma Park, Maryland, United States
Deborah Heart
Browns Mills, New Jersey, United States
Cardiovascular Associates of the Delaware Valley
Haddon Heights, New Jersey, United States
Our Lady of Lourdes Medical Center
Haddon Heights, New Jersey, United States
Holy Name Medical Center
Teaneck, New Jersey, United States
Gotham Cardiovascular Research, PC
New York, New York, United States
Columbia University Medical Center, Center for Interventional Vascular Therapy
New York, New York, United States
CarolinaEast Health Center
New Bern, North Carolina, United States
Rex Healthcare
Raleigh, North Carolina, United States
Sanford Research/USD/Sanford Clinic
Fargo, North Dakota, United States
Riverside Methodist Hospital / MidWest Cardiology Research Foundation
Columbus, Ohio, United States
Holy Spirit Hospital
Camp Hill, Pennsylvania, United States
Allegheny General Hospital/Forbes Hospital
Pittsburgh, Pennsylvania, United States
Miriam Hospital
Providence, Rhode Island, United States
Cardiovascular Research Institute of Dallas
Dallas, Texas, United States
Sentara Vascular Specialists
Norfolk, Virginia, United States
Providence Sacred Heart Medical Center / Providence Spokane Cardiology
Spokane, Washington, United States
Wisconsin Heart Hospital
Milwaukee, Wisconsin, United States
Aurora St. Luke's Medical Center / Aurora Medical Group
Milwaukee, Wisconsin, United States
Imelda Hospital / Flanders Medical Research Program
Bonheiden, , Belgium
A.Z. Sint-Blasius Hospital / Flanders Medical Research Program
Dendermonde, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G; VIVA Physicians, Inc. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007 May 1;69(6):910-9. doi: 10.1002/ccd.21104.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FSS-0003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.